NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as...

NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology
as Vice President of Drug Development and Regulatory Affairs

NEW YORK, July 6 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is
pioneering the pre-disease collection, processing and long-term storage of
adult stem cells for future medical need, announced today it has appointed
Alan G. Harris, M.D., Ph.D., FACP, FRCP, as the Company's Vice President of
Drug Development and Regulatory Affairs.

Among his responsibilities in this position will be overseeing NeoStem's
therapeutic development activities and interfacing with the Chairman of the
Scientific Advisory Board to assist in the execution of the Company's
scientific vision. This will include overseeing the Company's regulatory
activities, working to advance NeoStem's intellectual property portfolio and
licensed technologies, assisting in the development of a chronic wound care
program and developing a regulatory pathway for commercializing stem cell
therapy, including assisting in developing very small embryonic like (VSEL)
stem cell therapy in multiple clinical indications. Upon the completion of
the Company's proposed acquisition of a 51% interest in Suzhou Erye
Pharmaceuticals Company, Ltd., which the Company anticipates closing no later
than the fourth quarter of 2009, Dr. Harris is expected to assist in bringing
new drugs to China to enhance Erye's pipeline in an effort to increase
revenues and provide a higher margin business through their already
established 30 province distribution.

Dr. Harris has over 20 years of experience working in clinical drug
development in multiple therapeutic areas in the pharmaceutical and
biotechnology industries, having conducted and overseen numerous clinical
trials in over 30 countries including China. He was recently Senior VP of R&D
and Chief Medical Officer at NPS Pharmaceuticals in NJ, where he successfully
launched two Phase III registration programs in Gastroenterology and
Endocrinology. Previously he served as Chief Medical Officer at Manhattan
Pharmaceuticals, Inc., after serving as Therapeutic Head of the Worldwide
Medical Endocrine Care group at Pfizer Inc, New York and, earlier, as Vice
President, Global Healthcare Research & Outcomes and Senior Director of
Medical & Scientific Affairs at Schering-Plough Corp., NJ, where he was
involved in the joint venture with Merck in the clinical development of the
novel cholesterol medication, ezetimibe (Zetia). Dr. Harris earned his MD from
the Louis Pasteur Faculty of Medicine, University of Strasbourg, France, and
his Ph.D. in endocrinology from Erasmus University, Rotterdam, The
Netherlands. He was appointed Associate Professor of Medicine at UCLA School
of Medicine and Director of the Division of Clinical Pharmacology in the
Department of Medicine and Medical Director of the Dept of Technology
Development and Transfer and Clinical Trials at Cedars-Sinai Medical Center.
Dr. Harris during his tenure at Sandoz (Novartis) Pharma in Switzerland,
developed octreotide (Sandostatin(R)) for the treatment of hormone producing
tumors of the gut and pituitary. He is currently Adjunct Professor of
Pharmacology at NYU Medical School and Visiting Professor of Medicine in the
Dept of Endocrinology at Liege University Medical School, Belgium and in the
Dept of Clinical Pharmacology at the University Hospital of Lausanne in
Switzerland. Dr. Harris is a Fellow of the American College of Physicians, the
Royal College of Physicians (UK), the Royal Society of Medicine (UK) and the
American College of Clinical Pharmacology. He has served on the editorial
boards of several international peer reviewed medical journals and has
authored 119 peer reviewed scientific papers in the fields of endocrinology,
diabetes mellitus, gastroenterology, oncology, cardiology, allergy, immunology
and respiratory medicine. He served on the NIH Center for Scientific Review
Special Emphasis Panel for Clinical Cardiovascular Sciences Study Section and
is currently a Trustee of the NYU Hospital for Joint Diseases.

Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are
extremely pleased to have Dr. Harris join our management team at NeoStem. His
extensive achievements in the academic and entrepreneurial worlds of medicine
indicate the range of his talents that will support the multifaceted growth of
our company that we anticipate over the coming years."

Dr. Harris stated, "I look forward very much to working with Dr. Smith and her
team on the exciting and creative medical and business opportunities that
NeoStem has under way, both in the United States and abroad. This is an
extraordinary young company with great potential for leadership in the
burgeoning field of stem cell therapies, and I'm delighted to play a part in
its development."

About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are
focused on enabling people to donate and store their own (autologous) stem
cells when they are young and healthy for their personal use in times of
future medical need. The Company has also entered into research and
development through the acquisition of a worldwide exclusive license to
technology to identify and isolate VSELs (very small embryonic-like stem
cells), which have been shown to have several physical characteristics that
are generally found in embryonic stem cells and is pursuing other technologies
to advance its position in the field of stem cell tissue regeneration. For
more information, please visit: www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. The Company's
actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors that could
cause future results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk Factors" described
in the Company's Annual Report on Form 10-K for the fiscal year ended December
31, 2008 and the Company's other periodic filings with the Securities and
Exchange Commission. The Company's further development is highly dependent on
future medical and research developments and market acceptance, which is
outside its control.

CONTACT:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com

SOURCE NeoStem, Inc.

Robin Smith, Chief Executive Officer of NeoStem, Inc., +1-212-584-4180,
rsmith@neostem.com